Please assess the completion status of the following clinical trial:

Trial Title: Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes~3. Unmedicated intraocular pressure \>20mmHg and \<36mmHg in both eyes at 2 qualification visits. Both eyes had to qualify at all qualification visits~4. Corrected visual acuity equivalent to 20/200 Snellen or better~5. Able to give informed consent and follow study instructions~Exclusion Criteria:~1. Clinically significant ocular disease~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles~3. Unmedicated Intraocular pressure ≥36mmHg~4. Use of more than 2 ocular hypotensive medications within 30 days of screening~5. Known hypersensitivity to any component of the formulation~6. Previous glaucoma surgery or refractive surgery~7. Ocular trauma within 6 months prior to screening~8. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening~9. Recent or current ocular infection or inflammation in either eye~10. Used ocular medication in either eye of any kind within 30 days of screening~11. Mean central corneal thickness \>620µm at screening~12. Any abnormality preventing reliable applanation tonometry of either eye~13. Clinically significant abnormalities in lab tests at screening~14. Clinically significant systemic disease~15. Participation in any investigational study within 60 days prior to screening~16. Used any systemic medication that could have a substantial effect on intraocular pressure within 30 days prior to screening~17. Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PG324 Ophthalmic Solution 0.02%/0.005% (Type: EXPERIMENTAL): Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
- AR-13324 Ophthalmic Solution 0.02% (Type: ACTIVE_COMPARATOR): Netarsudil 0.02% ophthalmic solution
- Latanoprost Ophthalmic Solution 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).